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Histone deacetylases have emerged as an important therapeutic target for the treatment of cancer. 
Genome-wide histone hypoacetylation causes many cancers. Recently, inhibitors of histone 
deacetylases (HDAC) have emerged as an important class of anticancer agents. Various side effects 
like myocardium damage and bone marrow depression even leading to cell death have been observed 
in the treatment of caner cells using HDAC inhibitors. The discovery and development of type-specific 
HDAC inhibitors is of both research and clinical interests. Ligand based pharmacophore modelling is 
playing a key role for the identification of ligand features for the particular targets. We present a model 
for designing the pharmacophore onto the set of 70 compounds of three different classes and two 
subclasses. The ligand based pharmacophore model has been identified in order to facilitate the 
discovery of type specific anticancer HDAC inhibitors. The result indicates that the in silico methods 
are useful in predicting the biological activity of the compound or compound library by screening it 
against a predicted pharmacophore. Ligand Scout 2.02 has been used to predict the pharmacophore 
features for anticancer HDAC inhibitors and the distances between pharmacophore features have been 
calculated through the software Jmol. The proposed model has been validated by docking the MS275 
compound into the binding pocket of Human HDAC8. Our discovery will help in the identification of 
more specific anticancer human HDAC inhibitors.  
 






More effective anticancer drug production with novel 
modes of action is today’s need (Sikora et al., 1999; 
Gelmon et al., 1999). Oncologists are aware of the fact 
that new drug discovery must target the developing 
mechanism of tumour in order to improve the therapeutic 
efficiency (Qianbin and Wenfang, 2005). Many transcription 
regulating proteins are themselves deregulated in cancer 
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Histone deacetylases (HDACs) is one of such important 
family of proteins which are deregulated in cancer 
(Walkinshaw and Yang, 2008). Cancer can result from 
aberrations in chromatin modifying proteins such as 
HDACs and chromatin (Walkinshaw and Yang, 2008). 
Disruption of HDAC activity may play an important role in 
the uncontrolled cell growth of cancer (Chen et al., 2003). 
In the discovery of drugs, HDAC has become a novel 
target for the treatment of cancer and other diseases 
(Marks et al., 2001). Over the past few years, the number 
of HDAC enzyme subtypes has expanded considerably 
offering opportunities for the development of HDAC 
inhibitors with improved specificity (Juvale et al., 2006). 
With continued research and development, in the near 
future, histone deacetylase inhibitors (HDACI’s) are likely 
to figure prominently in cancer treatment plans (Walkinshaw 
and Yang, 2008). 
The first and only approved (in 2006) histone deacetylase  




inhibitor, Zolinza by the U.S Food and Drug Administration 
is used for the treatment of Cutaneous T-cell Lymphoma 
(Walkinshaw and Yang, 2008). In general, histone 
deacetylase inhibitors are associated with certain toxicities 
(Minucci and Pelicci, 2006; Karagiannis and Osta, 2007). 
Intense research activities are ongoing in the pharma-
ceutical and academic laboratories toward improving the 
pharmacokinetic and therapeutic indices of current HDAC 
inhibitors (Chen et al., 2008a). The wide variety of structural 
HDAC inhibitors includes three molecular fragments, a 
linker domain which occupies the channel, a metal 
binding domain which interacts with the active site and 
surface recognition domain which interacts with the residues 
on the rim of the active site. In developing potent histone 
deacetylase inhibitors, this three-component concept has 
proved to be successful (Jung et al., 1999; Sternson et 
al., 2001). 
The pharmacophore model may provide guidance for 
the rational design to discover novel histone deacetylase 
inhibitors by highlighting the important binding features of 
HDAC ligands (Chen et al., 2008b).  
The knowledge of common properties of the binding 
group is essential for the determination of the type of 
inhibitor binding the target. Major goal of modern drug 
design is identification and development of new ligands 
with high affinity of binding toward a given protein 
receptor. A very useful model for achieving this goal is 
pharmacophore. 
Many scientists have achieved utilization of a ligand-
based approach like QSAR and 3D pharmacophores to 
provide an alternative and complementary tool for drug 
design of HDAC inhibitors (Katritzky et al., 2007; Ragno 
et al., 2006; Wagh et al., 2006; Chen et al., 2008b; 
Vadivelan et al., 2008). In order to gain further insight into 
the structural requirements of HDAC inhibitors, a novel 
three dimensional quantitative structure-activity relationship 
pharmacophore model is developed and further evaluated 
(Chen et al., 2008b). The pharmacophore model was 
derived from hydroxamic acid derivatives (Chen et al., 
2008b). The pharmacophore presented consists of one 
hydrogen-bond acceptor (HBA), one hydrogen bond 
donor (HBD) and three hydrophobic features (Chen et al., 
2008b). Compound MS-275 has been docked into the 
binding pocket of histone deacetylase like protein (HDLP) 
in order to check the proposed pharmacophore (Chen et 
al., 2008b). 
A pharmacophore model of hydroxamic acid derivatives 
which was identified consisted of two HBAs and three 
hydrophobic features (Chen et al., 2009). Another pharma-
cophore model highlights important binding features of 
HDAC ligands and may provide guidance for the rational 
design to discover novel hydroxamate HDAC 1 selective 
inhibitors (Liqin et al., 2009). This pharmacophore 
hypothesis consists of one HBA, one aromatic ring and 
two hydrophobic groups (Liqin et al., 2009). 
In our studies, a 3D pharmacophore model is developed 





histone deacetylase inhibitors for the treatment of human 
cancer which has not been reported earlier. Various 
previously performed studies identified the pharmacophore 
of only hydroxamate derivatives of HDACIs. Current 
studies involved the pharmacophore identification of not 
only hydroxamates but also benzamide and bi-phenyl 
derivatives. So a unique pharmacophore based upon 
three major groups of HDACIs has been proposed in 
order to gain further insight into the structural requirements 
of HDACs. The proposed model is validated by docking 
the MS-275 compound into the binding pocket of Human 
HDAC8. 
Our studies will help towards the identification of more 
potent human anticancer histone deacetylase inhibitors. 
With continued research and development, in the near 
future, HDACIs are likely to figure prominently in cancer 
treatment plans.  
 
 
MATERIALS AND METHODS 
 
The study was carried out using the software Ligand Scout (version 
2.03[i2_001]). Ligand Scout is a software tool that allows the rapid 
and transparently deriving 3D chemical feature-based pharma-
cophores from structural data of macromolecule ligand complexes 
in a fully automated and convenient way (Steindl et al., 2006). 
Ligand Scout runs on all common operating systems and several 
successful application examples have been published (Schuster 
and Langer, 2005; Schuster et al., 2006). 
The training set consisted of 70 compounds and was selected to 
generate the ligand based pharmacophore model. The compounds 
present in the set were different groups of hydroxamate, benzamide 
(Suzuki et al., 1999) and bi-phenyl derivatives (Dallavalle et al., 
2009). The two groups chosen are basically the aliphatic and 
aromatic hydroxamates (Remiszewski et al., 2002; Woo et al., 
2002; Lavoie et al., 2001; Massa et al., 2001). 
Ligand based pharmacophore model generation was performed 
with Ligand Scout using default settings. The pharmacophore for 
each group of compounds and MS-275 has been generated and 
the distances among the pharmacophoric features of the ligands 
have been calculated using the software Jmol (jmol.org).  Jmol is a 
Java viewer which is open source and is used for three dimensional 
structures of compounds, with their features, materials, biomolecules 
and crystals (Herráez, 2007). 
The pharmacophore of the above mentioned groups and 
subgroups have been superimposed in order to get the common 
pharmacophore of anticancer HDAC inhibitors. The distances 
among the pharmacophoric features of the common and unique 
pharmacophore were then calculated. 
Model validation has been performed through molecular docking 
studies which have been performed through Autodock 4.0 (Morris 
et al., 1998) and VMD (Humphrey et al., 1996). Compound MS-275 
have been docked into the binding pocket of Human HDAC8 with 
PDB id 1T69 obtained from Protein Data Bank (rcsb.org). Autodock 
has been applied with great success in the prediction of bound 
conformations of enzyme inhibitor complexes, peptide antibody 




RESULTS AND DISCUSSION 
 
The pharmacophore generated  by  Ligand  Scout for  the  
















training set showed three main features as hydrogen 
bond acceptors, hydrogen bond donors and aromatic 
rings. The pharmacophore generated for the chosen 
group of compounds showed consistency in the above 
features. The representative pharmacophores of each 
group and subgroups are shown in Figures 1, 2, 3 and 4. 
The pharmacophore of MS-275 are shown in Figure 5.  
These figures show the 3D and 2D views of the 
pharmacophores. The features identified in green colors 
are the HBDs, red colored are HBAs and the aromatic 
rings are shown in blue color in both views. All the ligands 
showed consistency in these three features. Similarly, all 
70 ligands showed similar features. On the whole, the 
pharmacophoric features for each are shown in Table 1. 
The pharmacophores of all the compounds were then 
matched and a unique pharmacophore was identified 
after a detailed analysis. Similar features were identified 
after analysing  the pharmacophores   of  all  compounds  
















generated by Ligand Scout. The similar features of all the 
compounds were then superimposed and merged into a 
single pharmacophore. Superimposed ligands (all) along 
with MS275 are shown in Figure 6. 
The orange colored circles in Figure 6 show the super-
imposed features in the ligands. The uniquely identified 
pharmacophore are shown in Figure 7. 
On the whole, the representative pharmacophoric features 
for each group and MS275 are shown in Table 2. 
Our common featured pharmacophore predicted for 
three groups and two sub-groups of anticancer HDAC 
inhibitors and MS275 (Table 2 and Figure 7) is as; three 
HBAs (shown by red circles), three HBDs (two green 
circles and one green arrow) and two aromatic rings (shown 
by blue circles).  
Chen et al. (2008) presented the pharmacophore of 
HDAC inhibitors as having one hydrogen bond acceptor, 
one hydrogen bond donor and three hydrophobic features. 
Like wise Chen et al. (2009) and Liqin et al. (2009) 
presented the pharmacophores of anticancer HDAC 
inhibitors using only hydroxamates derivatives. 
So our pharmacophore features based  on  the  studies  










Table 1. Pharmacophoric features of each group of ligands. 
 






Aliphatic hydroxamtes  + + + 
Aromatic hydroxamtes + + + 
Benzamides derivatives + + + 






Figure 6.  Aligned features of the all compounds. 










Table 2. Total pharmacophoric features of each group of ligands and MS-275. 
 






Aliphatic Hydroxamtes  Four Three Two 
Aromatic Hydroxamtes Four Three Two 
Benzamides Derivatives Four Three Three 
Bi-phenyl Derivatives Three Three Two 




Table 3. Pharmacophoric triangle distances of each group of ligands. 
 
Ligands HBA-HBD (nm) HBD-Ar (nm) HBA-Ar (nm) 
Aliphatic hydroxamtes 0.0816 – 0.6543 0.3655 – 0.9214 0.8011 – 0.99 
Aromatic hydroxamtes 0.1393 – 0.5194 0.1936 – 0.3462 0.1549 – 0.4664 
Benzamides derivatives 0.1427 – 0. 6221 0.2971- 0.8912 0.1427 – 0.3776 
Bi-phenyl derivatives 0.1824 – 0.6664 0.1429 – 0.696 0.251 – 0.7748 




of three major groups have improved the features more. 
In this way, the pharmacophore has not only been 
restricted to hydroxamate derivatives but other groups 
have also been included. 
The distance triangle measured between the common 
pharmacophore features of each group of compounds 
and MS275 using Jmol is shown in Table 3. The distance 
ranges from minimum to maximum and have been 
measured between the HBA and HBD, HBA and aromatic 
ring and HBD and aromatic ring. The distances among 
common pharmacophoric features between the predicted 
pharmacophore are shown in Figure 8. The distances 
between aromatic and HBD range from 0.1429 to 0.9214 
nm, between aromatic to HBA range from 0.1427 to 0.99 
nm and between HBA to HBD range from 0.0816 to 
0.6664 nm.  
The comparison of the pharmacophoric features at 
each step along with the standard MS275 shows the 
validation of predicted pharmacophore model. As the 
standard MS275 showed similar pharmacophoric features  
















like the test data, it has been docked into the binding 
cavity of the Human HDAC8. The docked ligand into the 
cavity and the binding interactions are shown in Figure 9. 
The important binding interactions which include hydrogen, 
hydrophobic and ionic interactions are shown in Figure 9. 
The figure shows the interactions at particular distances.  




The binding interactions of MS275 include 6 hydrogen 
bonds, 9 hydrophobic interactions and 2 ionic bonds. The 
hydrogen bonds include H of the ligand with the O’s of 
ASP157 at distances of 2.62 and 2.48, with the O’s of 
ASP101 at 3.04 and 3.10, with the O of PHE152 at 
3.45 and with N of GLN263 at 4.13. The ionic inte-
ractions include N of ARG37 with the O of Ligand at 
4.25 and O of ASP178 with the N of ligand at 4.69. 
The hydrophobic interactions include the C’s of ligand 
with the C’s of TRP141 at 2.12, at 3.80, at 2.31 and 
3.08, of HIS142 at 2.13 and 3.39, of GLN263 at 
3.14 and 2.73 and last of the HIS143 at 3.45. 
The actively docked conformation of the MS275 into 
the cavity and the strong binding interactions of the ligand 
with HDAC8 showed the validation of the proposed 
model. The strong interactions of the ligand with the 
human target protein show the validation of proposed 
pharmacophore model like Chen et al. (2008) did with the 
HDLP. 
Our predicted pharmacophore for the three major 
groups and two sub groups of anticancer HDAC inhibitors 
will help in the identification of type specific drugs. This 
model has broadened the vision for the generation of 
more specific drugs for human cancers and it opens the 
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